SOTAC PHARMACEUTICALS LIMITED

(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office:

Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GICD - II,

Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451



Date: April 29, 2023

To,
The Manager-Listing
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Mumbai – 400051

Respected Sir/Ma'am,

Sub: Update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that Sotac Healthcare Private Limited (Subsidiary company - 71% stake), has received new Purchase order of Approx. 2.70 Cr tablet plan from one of the esteemed renowned pharmaceutical company of India, for supply of Betalactum product which is Amoxyclave 625 mg tablets. The total purchase order tablet plan is of Approx.Rs.13.58 Crores to be executed till September 2023.

Today our subsidiary Company received a purchase order of Rs. 4.24 Crores approximately for 84 Lakhs tablets out of Approx. 2.70 Cr tablets for Betalactum product which needs to complete till June, 2023. Due to completion of this Purchase order, it will attribute significantly towards top line and profitability of the subsidiary company and as well as it will enhance the customer base.

Further Details with respect to said order as required under regulation 30 of listing regulations read with SEBI circular CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided herewith.

You are requested to kindly note the same.

Thanking you,

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel Chairman and Managing Director

DIN: 07252252 Place: Ahmedabad

Encl: A/a



SOTAC PHARMACEUTICALS LIMITED

(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office:

Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GICD - II,

Sanand, Ahmedabad - 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451



<u>Details as required under regulation 30 of listing regulations read with SEBI circular CIR/CFD/CMD/4/2015 dated</u> <u>September 09, 2015</u>

Details of Order are as follows:-

Sr. No.	Particulars	Details
1.	Name of the entity awarding the order(s)/contract(s);	*
2.	whether order(s) / contract(s) is awarded to domestic/international entity	Domestic
3.	Nature of Order/Contract, Significant terms & Conditions of order, Broad considerations & Size of Order	Sotac Healthcare Private Limited (Subsidiary company - 71% stake), has received new Purchase order of Approx. 2.70 Cr tablet plan from one of the esteemed renowned pharmaceutical company of India, for supply of Betalactum product which is Amoxyclave 625 mg tablets. The purchase order tablet plan is of Approx. Rs.13.58 Crores to be executed till September 2023. Today our subsidiary Company received a purchase order of Rs. 4.24 Crores approximately for 84 Lakhs tablets out of Approx. 2.70 Cr tablets for Betalactum product which needs to complete till June, 2023.
4.	Time period by which the order(s)/contract(s) is to be executed;	From April 2023 to June, 2023
5.	Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s)/contract(s)? If yes, nature of interest and details thereof	Yes(Received by Sotac Healthcare Private Limited being Subsidiary Company in which our company is holding - 71% stake)
6.	Whether the order(s)/contract(s) would fall within related party transactions? If yes, whether the same is done at "arm's length"	No

^{*}Note: We have received purchase order from one of the esteemed renowned pharmaceutical company of India and due to Privacy terms with such Client Company and mutual understanding we are unable to disclose its name.

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel Chairman and Managing Director

DIN: 07252252 Place: Ahmedabad

